Company profile

  • Committed to Life-Threatening Infectious Diseases
  • Strong, experienced team of scientists
  • Innovative pipeline
  • Track-record of success



Backed by the majority investors, founders and previous owners of Hexal, Drs. Strüngmann, AiCuris was founded in March 2006 as a spin-off of the anti-infectives division of Bayer Health Care, a business unit with a long history of successful anti-infective drug development.
Since then, AiCuris has become a highly focused pharmaceutical company for the discovery, research, and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

Our Mission

AiCuris‘ mission is the development of innovative drugs against severe and life-threatening infectious diseases with high medical need.

AiCuris aims to be THE successful innovator for antiviral and antibacterial therapy.

Differentiation from existing therapies is achieved using novel drug classes and/or mechanisms of action. In this way, our drugs are resistance-breaking by design.


AiCuris is led by an experienced management team. At the company’s heart is a group of scientists with broad international experience in drug discovery and development, and know-how gained at both large and small pharmaceutical companies. The team has core expertise in pharmacology, microbiology, virology, pharmacokinetics, medicinal chemistry and clinical development.


AiCuris’ head office and research laboratories are located at the Pharma- and Chemistry Park in Wuppertal, Germany, where the company occupies 3.000 square meters of purpose built biology and pharmacokinetics facilities for the discovery and development of novel anti-infective agents with a current staff of approx. 65 employees.